secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001171843-25-001799
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose reports FY 2024 net loss of $25.4M; cash runway to April 2025
--------------------------------------------------------------------

- Net loss $25.4M vs $51.2M in FY 2023; diluted EPS ($36.38) vs ($227.43).
- Cash and equivalents $6.7M as of Dec 31, 2024; expect funding through April 2025.
- TUS+VEN+AZA triplet TUSCANY trial advancing; 40mg achieved CRs; 80mg dosing started.
- $1.5M of Hanmi debt converted to 409,063 common shares; Hanmi stake capped at 19.99%.
- Regained Nasdaq minimum bid compliance; still not in compliance with $2.5M equity requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325001799/0001171843-25-001799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325001799/f8k_032825.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer